1160 s.
132(VI)-136(VIII), 296(160) s. : tab. ; 24 cm
Monographs in virology ; vol. 5
VIII, 81 s. : tab. ; 26 cm
Archives of virology ; Supplement. 10
586 s. : obr., tab., grafy ; 32 cm
Archives of virology ; Supplement. 2
450 s.
- MeSH
- Classification MeSH
- Humans MeSH
- Terminology as Topic MeSH
- Viruses classification MeSH
- Check Tag
- Humans MeSH
- MeSH
- Classification MeSH
- Humans MeSH
- Terminology as Topic MeSH
- Viruses classification MeSH
- Check Tag
- Humans MeSH
BACKGROUND: To derive a list of opportunistic infections (OI) through the analysis of the juvenile idiopathic arthritis (JIA) patients in the Pharmachild registry by an independent Safety Adjudication Committee (SAC). METHODS: The SAC (3 pediatric rheumatologists and 2 pediatric infectious disease specialists) elaborated and approved by consensus a provisional list of OI for use in JIA. Through a 5 step-procedure, all the severe and serious infections, classified as per MedDRA dictionary and retrieved in the Pharmachild registry, were evaluated by the SAC by answering six questions and adjudicated with the agreement of 3/5 specialists. A final evidence-based list of OI resulted by matching the adjudicated infections with the provisional list of OI. RESULTS: A total of 772 infectious events in 572 eligible patients, of which 335 serious/severe/very severe non-OI and 437 OI (any intensity/severity), according to the provisional list, were retrieved. Six hundred eighty-two of 772 (88.3%) were adjudicated as infections, of them 603/682 (88.4%) as common and 119/682 (17.4%) as OI by the SAC. Matching these 119 opportunistic events with the provisional list, 106 were confirmed by the SAC as OI, and among them infections by herpes viruses were the most frequent (68%), followed by tuberculosis (27.4%). The remaining events were divided in the groups of non-OI and possible/patient and/or pathogen-related OI. CONCLUSIONS: We found a significant number of OI in JIA patients on immunosuppressive therapy. The proposed list of OI, created by consensus and validated in the Pharmachild cohort, could facilitate comparison among future pharmacovigilance studies. TRIAL REGISTRATION: Clinicaltrials.gov NCT01399281; ENCePP seal: awarded on 25 November 2011.
- MeSH
- Antirheumatic Agents therapeutic use MeSH
- Child MeSH
- Pharmacovigilance MeSH
- Herpes Zoster diagnosis etiology MeSH
- Immunocompromised Host * MeSH
- Arthritis, Juvenile complications drug therapy pathology MeSH
- Cohort Studies MeSH
- Humans MeSH
- Opportunistic Infections diagnosis etiology MeSH
- Child, Preschool MeSH
- Registries statistics & numerical data MeSH
- Severity of Illness Index MeSH
- Tuberculosis diagnosis etiology MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
Members of the family Secoviridae are non-enveloped viruses with mono- or bipartite (RNA-1 and RNA-2) linear positive-sense ssRNA genomes with the size of the RNAs combined ranging from 9 to 13.7 kb. They are related to picornaviruses and are classified in the order Picornavirales. The majority of known members infect dicotyledonous plants and many are important plant pathogens (e.g. grapevine fanleaf virus and rice tungro spherical virus). This is a summary of the current International Committee on Taxonomy of Viruses (ICTV) report on the taxonomy of the family Secoviridae available at www.ictv.global/report/secoviridae.
